Jaqueline Corrigan-Curay, who serves as acting head of the FDA’s Center for Drug Evaluation and Research, will depart next ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

The funds will support Phase 2 testing of a drug the company believes to be able to safety home in on AMPA receptors, an ...